Hyewon Ko

Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: Mineralization and its effect on tumor targetability in vivo

The in vivo stability and tumor targetability of self-assembled polymeric nanoparticles are crucial for effective drug delivery. In this study, to develop biostable nanoparticles with high tumor targetability, poly(ethylene glycol)-conjugated hyaluronic acid nanoparticles (PEG-HANPs) were mineralized through controlled deposition of inorganic calcium and phosphate ions on the nanoparticular shell via a sequential addition method. The resulting nanoparticles (M-PEG-HANPs) had a smaller size (153.7±4.5nm) than bare PEG-HANPs (265.1±9.5nm), implying that mineralization allows the formation of compact nanoparticles. Interestingly, when the mineralized nanoparticles were exposed to acidic buffer conditions (<pH6.5), their sizes increased rapidly due to dissolution of the inorganic minerals. Doxorubicin (DOX), chosen as the model anticancer drug, was effectively encapsulated into the bare and mineralized nanoparticles. For bare PEG-HANPs, DOX was released in a sustained manner and its release rate was not dependent on the pH of the solution. On the other hand, DOX release from M-PEG-HANPs was pH-dependent: i.e. DOX was slowly released from nanoparticles under physiological condition (pH7.4), whereas its release rates were much higher at mildly acidic environments (<pH6.5). From in vivo biodistribution study, it was found that M-PEG-HANPs could reach the tumor site more effectively than bare PEG-HANPs. The antitumor efficacy of DOX-loaded nanoparticles was evaluated after systemic administration into the tumor-bearing mice. Of the samples tested, the most effective antitumor efficacy was observed for DOX-loaded M-PEG-HANPs. Overall, these results suggest that M-PEG-HANPs could be a promising carrier for an anticancer drug.

Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.

For drug delivery nanocarriers to be a safe and effective therapeutic option, blood stability, tumor-targetability, and intracellular drug release features should be considered. In this study, to develop a potent drug delivery carrier that can meet the multiple requirements, we engineered a bioreducible core-crosslinked polymeric micelle based on hyaluronic acid (CC-HAM) by a facile method using d,l-dithiothreitol in aqueous conditions. The CC-HAM exhibited enhanced structural stability under diluted conditions with PBS containing FBS or sodium dodecyl sulfates. We also successfully encapsulated doxorubicin (DOX), chosen as a hydrophobic anti-cancer drug, in CC-HAMs with high loading efficiency (>80%). The drug release rate of CC-HAMs was rapidly accelerated in the presence of glutathione, whereas the drug release was significantly retarded in physiological buffer (pH7.4). An in vivo biodistribution study demonstrated the superior tumor targetability of CC-HAMs to that of non-crosslinked HAMs, primarily ascribed to robust stability of CC-HAMs in the bloodstream. Notably, these results correspond with the improved pharmacokinetics and tumor accumulation of DOX-loaded CC-HAMs as well as their excellent therapeutic efficacy. Overall, these results suggest that the robust, bioreducible CC-HAM can be applied as a potent doxorubicin delivery carrier for targeted cancer therapy.

Bioreducible shell-cross-linked hyaluronic acid nanoparticles for tumor-targeted drug delivery.

The major issues of self-assembled nanoparticles as drug carriers for cancer therapy include biostability and tumor-targetability because the premature drug release from and nonspecific accumulation of the drug-loaded nanoparticles may cause undesirable toxicity to normal organs and lower therapeutic efficacy. In this study, we developed robust and tumor-targeted nanocarriers based on an amphiphilic hyaluronic acid (HA)-polycaprolactone (PCL) block copolymer, in which the HA shell was cross-linked via a bioreducible disulfide linkage. Doxorubicin (DOX), chosen as a model anticancer drug, was effectively encapsulated into the nanoparticles with high drug loading efficiency. The DOX-loaded bioreducible HA nanoparticles (DOX-HA-ss-NPs) greatly retarded the drug release under physiological conditions (pH 7.4), whereas the drug release rate was markedly enhanced in the presence of glutathione, a thiol-containing tripeptide capable of reducing disulfide bonds in the cytoplasm. Furthermore, DOX-HA-ss-NPs could effectively deliver the DOX into the nuclei of SCC7 cells in vitro as well as to tumors in vivo after systemic administration into SCC7 tumor-bearing mice, resulting in improved antitumor efficacy in tumor-bearing mice. Overall, it was demonstrated that bioreducible shell-cross-linked nanoparticles could be used as a potential carrier for cancer therapy.

Bioreducible polymersomes for intracellular dual-drug delivery†

Stimuli-sensitive polymersomes, composed of amphiphilic block copolymers, have emerged as a promising nanocarrier for triggered release of anticancer drugs. In this study, we synthesized a bioreducible, amphiphilic triblock copolymer based on poly(ethylene glycol)-b-poly(lysine)-b-poly(caprolactone) bearing a disulfide bond (PEG-b-PLys-SS-PCL). Owing to its unique amphiphilicity, the copolymer formed self-assembled polymersomes (256 nm diameter) under aqueous conditions. These polymersomes were stable in physiological solution (pH 7.4), whereas they readily disintegrated under a reductive environment similar to an intracellular condition. The polymersomes could simultaneously encapsulate the hydrophobic camptothecin (CPT) in their membrane and the hydrophilic doxorubicin·hydrochloride (DOX·HCl) in their aqueous cores. The polymersomes released the drugs in a sustained manner under physiological conditions (pH 7.4), whereas the drug release rates dramatically increased in a reductive environment at 10 mM glutathione. From in vitro cytotoxicity tests, it was found that dual drug-loaded polymersomes showed significantly higher cytotoxicity to SCC7 cancer cells than those with the single drug. These results suggest that the polymersomes bearing the bioreducible linker have high potential as carriers for intracellular dual-drug delivery.

Long-Circulating Au-TiO2 Nanocomposite as a Sonosensitizer for ROS-Mediated Eradication of Cancer

Although sonodynamic therapy (SDT) has emerged as a potential alternative to conventional photodynamic therapy, the low quantum yield of the sonosensitizer such as TiO2 nanoparticles (NPs) is still a major concern. Here, we have developed hydrophilized Au-TiO2 nanocomposites (HAu-TiO2 NCs) as sonosensitizers for improved SDT. The physicochemical properties of HAu-TiO2 NCs were thoroughly studied and compared with their counterparts without gold deposition. Upon exposure of HAu-TiO2 NCs to ultrasound, a large quantity of reactive oxygen species (ROS) were generated, leading to complete suppression of tumor growth after their systemic administration in vivo. Overall, it was evident that the composites of gold with TiO2 NPs significantly augmented the levels of ROS generation, implying their potential as SDT agents for cancer therapy.

Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment.

ABSTRACT Introduction: Hyaluronic acid (HA) has emerged as a promising applicant for the tumor-targeted delivery of various therapeutic agents. Because of its biocompatibility, biodegradability and receptor-binding properties, HA has been extensively investigated as the drug delivery carrier. In this review, recent advances in HA-based nanomedicines are discussed. Areas covered: This review focuses on HA-based nanomedicines for the diagnosis and treatment of cancer. In particular, recent advances in HA-drug conjugates and HA-based nanoparticles for small molecular drug delivery are discussed. The bioreducible HA conjugates for small interfering ribonucleic acid delivery have been also discussed. Expert opinion: To develop a successful HA-based nanomedicine, it has to be prepared without significant deterioration of intrinsic property of HA. The chemical modification of HA with drugs or hydrophobic moieties may reduce the binding affinity of HA to the receptors. In addition, since the HA-based nanomedicines tend to accumulate in the liver after their systemic administration, new strategies to overcome this issue have to be developed.

Synthesis and physicochemical characterization of reduction-sensitive block copolymer for intracellular delivery of doxorubicin

AbstractAn amphiphilic diblock copolymer bearing the reduction-sensitive linker, composed of poly(ethylene glycol) (PEG) and hydrophobic poly(γ-benzyl L-glutamate) (PBLG), was prepared as the potential carrier of doxorubicin (DOX) via a facile synthetic method in the presence of a shell-sheddable PEG macroinitiator (PEG-SS-NH2). Owing to its amphiphilic nature, the copolymer (PEG-SS-PBLG) formed spherical micelles (137 nm in diameter) in aqueous conditions. The micelles were stable under the physiologic condition (pH 7.4) and were readily cleaved in the presence of glutathione (GSH), a tripeptide reducing the disulfide bond in the cytoplasm of the cell. DOX, chosen as a model anticancer drug, was effectively encapsulated into the hydrophobic core of the micelle with high loading efficiency (>75%). The micelle released DOX completely within 18 h at 10 mM GSH mimicking the intracellular condition, whereas only 34% of the drug was released from the micelle at 2 μM GSH. In vitro cytotoxicity tests revealed that DOX-loaded reduction-sensitive micelles are more toxic to SCC7 cells than reduction-insensitive control micelles. These results suggest that PEG-SS-PBLG is the promising carrier for the intracellular delivery of DOX.

In situ diselenide-crosslinked polymeric micelles for ROS-mediated anticancer drug delivery

Stimuli-responsive micelles have emerged as the drug carrier for cancer therapy since they can exclusively release the drug via their structural changes in response to the specific stimuli of the target site. Herein, we developed the in situ diselenide-crosslinked micelles (DCMs), which are responsive to the abnormal ROS levels of tumoral region, as anticancer drug carriers. The DCMs were spontaneously derived from selenol-bearing triblock copolymers consisting of polyethylene glycol (PEG) and polypeptide derivatives. During micelle formation, doxorubicine (DOX) was effectively encapsulated in the hydrophobic core, and diselenide crosslinks were formed in the shell. The DCMs maintained their structural integrity, at least for 6 days in physiological conditions, even in the presence of destabilizing agents. However, ROS-rich conditions triggered rapid release of DOX from the DOX-encapsulating DCMs (DOX-DCMs) because the hydrophobic diselenide bond was cleaved into hydrophilic selenic acid derivatives. Interestingly, after their systemic administration into the tumor-bearing mice, DOX-DCMs delivered significantly more drug to tumors (1.69-fold and 3.73-fold higher amount compared with their non-crosslinked counterparts and free drug, respectively) and effectively suppressed tumor growth. Overall, our data indicate that DCMs have great potential as drug carriers for anticancer therapy.

Biostable and bioreducible polymersomes for intracellular delivery of doxorubicin

To minimize the premature drug release of nanocarriers, we have developed chemically cross-linked bioreducible polymersomes (CLPMs) that can specifically release the drug inside cancer cells. Polymersomes were prepared using poly(ethylene glycol)-b-poly(lysine)-b-poly(caprolactone), a biocompatible triblock copolymer. To chemically cross-link the polymersomes, the primary amine of the triblock copolymer was reacted with a disulfide-containing cross-linker. Doxorubicin (DOX) was chosen as a model anti-cancer drug, and was effectively encapsulated into the CLPMs. The drug-loaded polymersomes greatly retarded the release of DOX under physiological conditions (pH 7.4), whereas the release rate of DOX increased remarkably in the presence of 10 mM glutathione, mimicking an intracellular environment. Microscopic observation showed that DOX-loaded CLPMs could effectively deliver the drug into an intracellular level of SCC7 cancer cells, leading to high cytotoxicity. These observations suggest that CLPMs are promising nanocarriers for intracellular DOX delivery.

Near-infrared light-triggered thermochemotherapy of cancer using a polymer-gold nanorod conjugate.

A biocompatible polymer-gold nanorod (P-AuNR) conjugate was developed as a thermo-chemotherapeutic nano-sized drug carrier for cancer therapy using near-infrared (NIR) light as an external trigger. The amphiphilic polymer, poly(ethylene glycol)-block-poly(caprolactone) (PEG-b-PCL) bearing a disulfide bond, was prepared using a facile synthetic route via copper(I)-free click chemistry and covalently linked to AuNR. The chemical structures and successful conjugation of PEG-b-PCL were analyzed using (1)H NMR and FT-IR. Doxorubicin (DOX), a hydrophobic anticancer drug, was effectively loaded into the hydrophobic PCL domain of P-AuNR through a simple dialysis method. P-AuNR showed longitudinal plasmon resonance absorption at the NIR region, thus generating heat under irradiation at 808 nm. Interestingly, exposure of P-AuNRs to NIR induced a structural change in the PCL block from a crystalline to an amorphous state, leading to the temporally controlled release of DOX. No significant release of DOX was observed from P-AuNRs under physiological conditions (pH 7.4), whereas the release rate of DOX was remarkably enhanced in response to NIR irradiation. In vitro cellular experiments to assess cytotoxicity and intracellular drug release behavior of DOX-P-AuNRs demonstrated that the release of DOX could be selectively regulated by NIR irradiation. Overall, DOX-P-AuNRs might have the potential to overcome the indiscriminate toxicity of free DOX.